Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company focused on translating novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. Peloton is initially targeting HIF-2α, a transcription factor which was previously thought to be intractable using a small molecule. The company is a leader in the field of HIF-2α biology and pioneered the first HIF-2α to enter into clinical development.
Translating Novel Scientific Insights Into First-In-Class Medicines
Peloton has opportunities to completely transform established treatment paradigms and improve patient outcomes in kidney cancer, VHL Disease, and other serious diseases.
Our drug discovery and development efforts focus on identifying novel compounds capable of modulating complex protein-protein interactions that drive disease which have eluded conventional small molecule approaches.
